Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients

Z. Mao; J. R. Baker; M. Takeuchi; H. Hyogo; A. Tjonneland; A. K. Eriksen; G. Severi; J. Rothwell; N. Laouali; V. Katzke; R. Kaaks; M. B. Schulze; D. Palli; S. Sieri; M. S. de Magistris; R. Tumino; Carlotta SACERDOTE; J. W. G. Derksen; I. T. Gram; G. Skeie; T. M. Sandanger; J. R. Quiros; M. Crous-Bou; Sanchez M. -J.; P. Amiano; S. M. Colorado-Yohar; M. Guevara; S. Harlid; I. Johansson; A. Perez-Cornago; H. Freisling; M. Gunter; E. Weiderpass; A. K. Heath; E. Aglago; M. Jenab; V. Fedirko

doi:10.1002/ijc.34449

Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients

Z. Mao, J. R. Baker, M. Takeuchi, H. Hyogo, A. Tjonneland, A. K. Eriksen, G. Severi, J. Rothwell, N. Laouali, V. Katzke, R. Kaaks, M. B. Schulze, D. Palli, S. Sieri, M. S. de Magistris, R. Tumino, Carlotta SACERDOTE, J. W. G. Derksen, I. T. Gram, G. SkeieT. M. Sandanger, J. R. Quiros, M. Crous-Bou, Sanchez M. -J., P. Amiano, S. M. Colorado-Yohar, M. Guevara, S. Harlid, I. Johansson, A. Perez-Cornago, H. Freisling, M. Gunter, E. Weiderpass, A. K. Heath, E. Aglago, M. Jenab, V. Fedirko

Dipartimento di Scienze della Salute

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Glyceraldehyde-derived advanced glycation end products (glycer-AGEs) could contribute to colorectal cancer development and progression due to their pro-oxidative and pro-inflammatory properties. However, the association of glycer-AGEs with mortality after colorectal cancer diagnosis has not been previously investigated. Circulating glycer-AGEs were measured by competitive ELISA. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for associations of circulating glycer-AGEs concentrations with CRC-specific and all-cause mortality among 1034 colorectal cancer (CRC) cases identified within the European Prospective Investigation into Cancer and Nutrition (EPIC) study between 1993 and 2013. During a mean of 48 months of follow-up, 529 participants died (409 from CRC). Glycer-AGEs were statistically significantly positively associated with CRC-specific (HRQ5 vs Q1 = 1.53, 95% CI: 1.04-2.25, Ptrend =.002) and all-cause (HRQ5 vs Q1 = 1.62, 95% CI: 1.16-2.26, Ptrend <.001) mortality among individuals with CRC. There was suggestion of a stronger association between glycer-AGEs and CRC-specific mortality among patients with distal colon cancer (per SD increment: HRproximal colon = 1.02, 95% CI: 0.74-1.42; HRdistal colon = 1.51, 95% CI: 1.20-1.91; Peffect modification =.02). The highest HR was observed among CRC cases in the highest body mass index (BMI) and glycer-AGEs category relative to lowest BMI and glycer-AGEs category for both CRC-specific (HR = 1.78, 95% CI: 1.02-3.01) and all-cause mortality (HR = 2.15, 95% CI: 1.33-3.47), although no statistically significant effect modification was observed. Our study found that prediagnostic circulating glycer-AGEs are positively associated with CRC-specific and all-cause mortality among individuals with CRC. Further investigations in other populations and stratifying by tumor location and BMI are warranted.

Lingua originale	Inglese
pagine (da-a)	2257-2268
Numero di pagine	12
Rivista	International Journal of Cancer
Volume	152
Numero di pubblicazione	11
DOI	https://doi.org/10.1002/ijc.34449
Stato di pubblicazione	Pubblicato - 2023

Keywords

advanced glycation end products
colorectal cancer
glyceraldehyde-derived advanced glycation end products
mortality
prospective study

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1002/ijc.34449

https://hdl.handle.net/11579/199563

Altri file e collegamenti

handle

Cita questo

Mao, Z., Baker, J. R., Takeuchi, M., Hyogo, H., Tjonneland, A., Eriksen, A. K., Severi, G., Rothwell, J., Laouali, N., Katzke, V., Kaaks, R., Schulze, M. B., Palli, D., Sieri, S., de Magistris, M. S., Tumino, R., SACERDOTE, C., Derksen, J. W. G., Gram, I. T., ... Fedirko, V. (2023). Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients. International Journal of Cancer, 152(11), 2257-2268. https://doi.org/10.1002/ijc.34449

@article{a468918bc2204e17bb986eaf264136f4,

title = "Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients",

abstract = "Glyceraldehyde-derived advanced glycation end products (glycer-AGEs) could contribute to colorectal cancer development and progression due to their pro-oxidative and pro-inflammatory properties. However, the association of glycer-AGEs with mortality after colorectal cancer diagnosis has not been previously investigated. Circulating glycer-AGEs were measured by competitive ELISA. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for associations of circulating glycer-AGEs concentrations with CRC-specific and all-cause mortality among 1034 colorectal cancer (CRC) cases identified within the European Prospective Investigation into Cancer and Nutrition (EPIC) study between 1993 and 2013. During a mean of 48 months of follow-up, 529 participants died (409 from CRC). Glycer-AGEs were statistically significantly positively associated with CRC-specific (HRQ5 vs Q1 = 1.53, 95% CI: 1.04-2.25, Ptrend =.002) and all-cause (HRQ5 vs Q1 = 1.62, 95% CI: 1.16-2.26, Ptrend <.001) mortality among individuals with CRC. There was suggestion of a stronger association between glycer-AGEs and CRC-specific mortality among patients with distal colon cancer (per SD increment: HRproximal colon = 1.02, 95% CI: 0.74-1.42; HRdistal colon = 1.51, 95% CI: 1.20-1.91; Peffect modification =.02). The highest HR was observed among CRC cases in the highest body mass index (BMI) and glycer-AGEs category relative to lowest BMI and glycer-AGEs category for both CRC-specific (HR = 1.78, 95% CI: 1.02-3.01) and all-cause mortality (HR = 2.15, 95% CI: 1.33-3.47), although no statistically significant effect modification was observed. Our study found that prediagnostic circulating glycer-AGEs are positively associated with CRC-specific and all-cause mortality among individuals with CRC. Further investigations in other populations and stratifying by tumor location and BMI are warranted.",

keywords = "advanced glycation end products, colorectal cancer, glyceraldehyde-derived advanced glycation end products, mortality, prospective study, advanced glycation end products, colorectal cancer, glyceraldehyde-derived advanced glycation end products, mortality, prospective study",

author = "Z. Mao and Baker, {J. R.} and M. Takeuchi and H. Hyogo and A. Tjonneland and Eriksen, {A. K.} and G. Severi and J. Rothwell and N. Laouali and V. Katzke and R. Kaaks and Schulze, {M. B.} and D. Palli and S. Sieri and {de Magistris}, {M. S.} and R. Tumino and Carlotta SACERDOTE and Derksen, {J. W. G.} and Gram, {I. T.} and G. Skeie and Sandanger, {T. M.} and Quiros, {J. R.} and M. Crous-Bou and -J., {Sanchez M.} and P. Amiano and Colorado-Yohar, {S. M.} and M. Guevara and S. Harlid and I. Johansson and A. Perez-Cornago and H. Freisling and M. Gunter and E. Weiderpass and Heath, {A. K.} and E. Aglago and M. Jenab and V. Fedirko",

year = "2023",

doi = "10.1002/ijc.34449",

language = "English",

volume = "152",

pages = "2257--2268",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "John Wiley and Sons Inc.",

number = "11",

}

Mao, Z, Baker, JR, Takeuchi, M, Hyogo, H, Tjonneland, A, Eriksen, AK, Severi, G, Rothwell, J, Laouali, N, Katzke, V, Kaaks, R, Schulze, MB, Palli, D, Sieri, S, de Magistris, MS, Tumino, R, SACERDOTE, C, Derksen, JWG, Gram, IT, Skeie, G, Sandanger, TM, Quiros, JR, Crous-Bou, M, -J., SM, Amiano, P, Colorado-Yohar, SM, Guevara, M, Harlid, S, Johansson, I, Perez-Cornago, A, Freisling, H, Gunter, M, Weiderpass, E, Heath, AK, Aglago, E, Jenab, M & Fedirko, V 2023, 'Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients', International Journal of Cancer, vol. 152, n. 11, pagg. 2257-2268. https://doi.org/10.1002/ijc.34449

TY - JOUR

T1 - Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients

AU - Mao, Z.

AU - Baker, J. R.

AU - Takeuchi, M.

AU - Hyogo, H.

AU - Tjonneland, A.

AU - Eriksen, A. K.

AU - Severi, G.

AU - Rothwell, J.

AU - Laouali, N.

AU - Katzke, V.

AU - Kaaks, R.

AU - Schulze, M. B.

AU - Palli, D.

AU - Sieri, S.

AU - de Magistris, M. S.

AU - Tumino, R.

AU - SACERDOTE, Carlotta

AU - Derksen, J. W. G.

AU - Gram, I. T.

AU - Skeie, G.

AU - Sandanger, T. M.

AU - Quiros, J. R.

AU - Crous-Bou, M.

AU - -J., Sanchez M.

AU - Amiano, P.

AU - Colorado-Yohar, S. M.

AU - Guevara, M.

AU - Harlid, S.

AU - Johansson, I.

AU - Perez-Cornago, A.

AU - Freisling, H.

AU - Gunter, M.

AU - Weiderpass, E.

AU - Heath, A. K.

AU - Aglago, E.

AU - Jenab, M.

AU - Fedirko, V.

PY - 2023

Y1 - 2023

N2 - Glyceraldehyde-derived advanced glycation end products (glycer-AGEs) could contribute to colorectal cancer development and progression due to their pro-oxidative and pro-inflammatory properties. However, the association of glycer-AGEs with mortality after colorectal cancer diagnosis has not been previously investigated. Circulating glycer-AGEs were measured by competitive ELISA. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for associations of circulating glycer-AGEs concentrations with CRC-specific and all-cause mortality among 1034 colorectal cancer (CRC) cases identified within the European Prospective Investigation into Cancer and Nutrition (EPIC) study between 1993 and 2013. During a mean of 48 months of follow-up, 529 participants died (409 from CRC). Glycer-AGEs were statistically significantly positively associated with CRC-specific (HRQ5 vs Q1 = 1.53, 95% CI: 1.04-2.25, Ptrend =.002) and all-cause (HRQ5 vs Q1 = 1.62, 95% CI: 1.16-2.26, Ptrend <.001) mortality among individuals with CRC. There was suggestion of a stronger association between glycer-AGEs and CRC-specific mortality among patients with distal colon cancer (per SD increment: HRproximal colon = 1.02, 95% CI: 0.74-1.42; HRdistal colon = 1.51, 95% CI: 1.20-1.91; Peffect modification =.02). The highest HR was observed among CRC cases in the highest body mass index (BMI) and glycer-AGEs category relative to lowest BMI and glycer-AGEs category for both CRC-specific (HR = 1.78, 95% CI: 1.02-3.01) and all-cause mortality (HR = 2.15, 95% CI: 1.33-3.47), although no statistically significant effect modification was observed. Our study found that prediagnostic circulating glycer-AGEs are positively associated with CRC-specific and all-cause mortality among individuals with CRC. Further investigations in other populations and stratifying by tumor location and BMI are warranted.

AB - Glyceraldehyde-derived advanced glycation end products (glycer-AGEs) could contribute to colorectal cancer development and progression due to their pro-oxidative and pro-inflammatory properties. However, the association of glycer-AGEs with mortality after colorectal cancer diagnosis has not been previously investigated. Circulating glycer-AGEs were measured by competitive ELISA. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for associations of circulating glycer-AGEs concentrations with CRC-specific and all-cause mortality among 1034 colorectal cancer (CRC) cases identified within the European Prospective Investigation into Cancer and Nutrition (EPIC) study between 1993 and 2013. During a mean of 48 months of follow-up, 529 participants died (409 from CRC). Glycer-AGEs were statistically significantly positively associated with CRC-specific (HRQ5 vs Q1 = 1.53, 95% CI: 1.04-2.25, Ptrend =.002) and all-cause (HRQ5 vs Q1 = 1.62, 95% CI: 1.16-2.26, Ptrend <.001) mortality among individuals with CRC. There was suggestion of a stronger association between glycer-AGEs and CRC-specific mortality among patients with distal colon cancer (per SD increment: HRproximal colon = 1.02, 95% CI: 0.74-1.42; HRdistal colon = 1.51, 95% CI: 1.20-1.91; Peffect modification =.02). The highest HR was observed among CRC cases in the highest body mass index (BMI) and glycer-AGEs category relative to lowest BMI and glycer-AGEs category for both CRC-specific (HR = 1.78, 95% CI: 1.02-3.01) and all-cause mortality (HR = 2.15, 95% CI: 1.33-3.47), although no statistically significant effect modification was observed. Our study found that prediagnostic circulating glycer-AGEs are positively associated with CRC-specific and all-cause mortality among individuals with CRC. Further investigations in other populations and stratifying by tumor location and BMI are warranted.

KW - advanced glycation end products

KW - colorectal cancer

KW - glyceraldehyde-derived advanced glycation end products

KW - mortality

KW - prospective study

KW - advanced glycation end products

KW - colorectal cancer

KW - glyceraldehyde-derived advanced glycation end products

KW - mortality

KW - prospective study

UR - https://iris.uniupo.it/handle/11579/199563

U2 - 10.1002/ijc.34449

DO - 10.1002/ijc.34449

M3 - Article

SN - 0020-7136

VL - 152

SP - 2257

EP - 2268

JO - International Journal of Cancer

JF - International Journal of Cancer

IS - 11

ER -

Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo